Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02325050 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
NCT02325050: Completed Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
NCT02325050 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 164 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02325050, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
Interventions
- OTHER Placebo
- BIOLOGICAL MVA-BN-Filo
- BIOLOGICAL Ad26. ZEBOV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2015-01-08 |
| Est. Completion | 2017-05-08 |
| Phase | Phase 1 |
What the finished NCT02325050 record still lists
NCT02325050 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02325050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02325050 about?
NCT02325050 is a clinical study titled "A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants". The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
What is the current status of trial NCT02325050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2015-01-08. Estimated completion is 2017-05-08.
What interventions are being tested in trial NCT02325050?
The interventions under investigation include: Placebo (OTHER), MVA-BN-Filo (BIOLOGICAL), Ad26. ZEBOV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02325050?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02325050's enrollment target sits among peer trials
164 335th of 2000 higher than 1,665 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI